The gene editing firm will concurrently offer 5 million shares to the public and $55 million worth of shares at the same price in a private placement.
BGI is seeking an IPO on a Shenzhen-based stock exchange, but the timing of when this might occur is unclear, FinanceAsia reports.
The CRISPR/Cas9 therapeutics firm could reap billions from the Regeneron collaboration, which includes $75 million up front and a $50 million private placement.
The company has scaled back its headcount from a peak of 115 employees to about 100 staff members, primarily on the commercial side.
The gene editing firm has sold all 5.9 million shares offered to the public as well as 885,000 shares in the fully exercised over-allotment option to the underwriters.
The Cambridge, Massachusetts-based gene editing firm will offer 5.9 million shares of common stock, for a total of $94.4 million.
The Cambridge, Massachusetts-based CRISPR therapy firm expects to price shares between $16 and $18.
The German molecular diagnostics firm plans to list on Euronext in Amsterdam and Euronext in Brussels.
Market worries earlier this week have left some in biotech shaken, FierceBiotech says.
The company filed to go public in March with plans to offer up to $60 million of its stock.
A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.
NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.
A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.
In Nature this week: epigenetic factors that prevent healthy aging and more.